Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Total RNA-seq in the A549 cell line after glucocorticoid re-induction

ABSTRACT: Total RNA-seq in the A549 cell line after glucocorticoid re-induction

PROVIDER: PRJEB42047 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR5000300_1.fastq.gz	Fastqsanger.gz
	ERR5000300_2.fastq.gz	Fastqsanger.gz
	ERR5000301_1.fastq.gz	Fastqsanger.gz
	ERR5000301_2.fastq.gz	Fastqsanger.gz
	ERR5000302_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Circularized chromosome conformation capture (4C-seq) in A549 cells after glucocorticoid re-induction

Project description:Circularized chromosome conformation capture (4C-seq) in A549 cells after glucocorticoid re-induction

| PRJEB42000 | ENA

Total RNA-seq in the A549 cell line after glucocorticoid re-induction

Project description:We performed total RNA-seq in the A549 cell line. Cells were treated with either 100 nM dexamethasone or 0.1% ethanol. After 4 hours, cells were washed 2x with PBS and cultured in hormone-free medium for 24 hours, after which cells were treated again for 4 hours with either 100 nM dexamethasone or 0.1% ethanol.

2021-05-03 | E-MTAB-9923 | biostudies-arrayexpress

Studying changes in chromatin accessibility in A549 cells by ATAC-seq after glucocorticoid re-induction

Project description:Studying changes in chromatin accessibility in A549 cells by ATAC-seq after glucocorticoid re-induction

| PRJEB41975 | ENA

Circularized chromosome conformation capture (4C-seq) in A549 cells after glucocorticoid re-induction

Project description:We performed 4C-seq in the A549 cell line to investigate changes in chromatin interactions at the ZBTB16 locus. Cells were treated with either 100 nM dexamethasone or 0.1% ethanol. After 4 hours, cells were washed 2x with PBS and cultured in hormone-free medium for 24 hours, after which cells were treated again for 4 hours with either 100 nM dexamethasone or 0.1% ethanol. Experiments were performed in two biological replicates. For each treatment, 4C-seq data were generated for the following two viewpoints: ZBTB16 promoter-proximal viewpoint coordinates: chr11:113929670-113930464 (hg19) ZBTB16 intronic viewpoint coordinates: chr11:114051224-114051804 (hg19)

2021-05-03 | E-MTAB-9915 | biostudies-arrayexpress

Studying changes in chromatin accessibility in A549 cells by ATAC-seq after glucocorticoid re-induction

Project description:We performed ATAC-seq in the A549 cell line. Cells were treated with either 100 nM dexamethasone or 0.1% ethanol. After 4 hours, cells were washed 2x with PBS and cultured in hormone-free medium for 24 hours, after which cells were treated again for 4 hours with either 100 nM dexamethasone or 0.1% ethanol.

2021-05-03 | E-MTAB-9912 | biostudies-arrayexpress

Genome-wide profiling of Glucocorticoid receptor binding in A549, Nalm-6, MEF WT and MEF GCN5/PCAF double knockout (ChIP-seq)

Project description:To identify the sequences responsible for recruitment of Glucocorticoid receptor (GR) to individual loci, we performed ChIP-seq in four cell lines : A549 (ATTC:CCL-185), Nalm-6 (ATCC:CRL-1567), immortalized mouse embryonic fibroblasts (MEFs)(PMID 21131905), and immortalized PCAF-/-; GCN5flox/ MEFs (PMID 21131905) upon glucocorticoid treatment (1.5 hrs, 1M dexamethasone).

2016-11-10 | E-MTAB-5113 | biostudies-arrayexpress

Total proteome analysis of A549 IFNR knockout and HepG2 cells

Project description:Total proteome analysis of A549 IFNR knockout and HepG2 cells

2023-08-08 | PXD031406 | Pride

Glucocorticoid Receptor (GR) ChIP-seq in A549 and U2OS cells

Project description:Glucocorticoid Receptor (GR) ChIP-seq in A549 and U2OS cells

| PRJNA685997 | ENA

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer

Project description:This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate the progression-free survival during maintenance therapy. Eligible patients will be treated within a 12-week induction therapy. Those patients achieving CR/PR or SD at 12 weeks and qualifying for maintenance treatment and re-induction treatment with all potential drug components, will be randomized in a ratio of 1:1 to receive chemotherapy plus panitumumab or chemotherapy alone during maintenance. In case of progression, re-induction treatment will be started.

| 2155383 | ecrin-mdr-crc

Transcriptome profiling of hESC-derived neural cultures after acute glucocorticoid induction

Project description:Transcriptome profiling of hESC-derived neural cultures after acute glucocorticoid induction

| PRJNA847999 | ENA